Status:

NOT_YET_RECRUITING

Dosimetric Differences and Clinical Significance Analysis Between Body Gamma Knife and VMAT Radiotherapy for Primary Liver Cance

Lead Sponsor:

Chifeng Tumor Hospital

Conditions:

Primary Liver Cancers

Eligibility:

All Genders

18-75 years

Brief Summary

To fill in the "Brief Summary" field, you need to provide clear, easy-to-understand information about the study for patients, families, and healthcare providers. Here's a suggested summary: This stud...

Eligibility Criteria

Inclusion

  • Aged 18-75 years.
  • Clinically or pathologically confirmed primary liver cancer; unsuitable for or - refusing surgery, with single tumor diameter ≤5 cm and ≤5 nodules.
  • ECOG PS score 0-1.
  • Liver function: Child-Pugh grade A or B.
  • Prothrombin time (PT) \< 4 seconds above the normal control range.
  • No hepatic encephalopathy or moderate to large ascites.
  • Renal and cardiopulmonary function basically normal.
  • Gastroscopy findings: no severe esophageal varices or active peptic ulcer.
  • Hemoglobin ≥90 g/L, WBC ≥3.0×10⁹/L, neutrophil ≥1.5×10⁹/L, platelet ≥40×10⁹/L.
  • No obvious cachexia; life expectancy \> 3 months.
  • Not pregnant; no HIV or syphilis infection.
  • Able to understand the study and sign informed consent.

Exclusion

  • History of portal hypertension, esophageal variceal bleeding, or related conditions.
  • History of anti-RHCC treatment or spontaneous tumor rupture.
  • Postoperative pathology indicates metastatic cancer or other primary cancers.
  • Cerebrovascular accident within 6 months before enrollment.
  • Severe lung disease; serum creatinine \> 1.25×the upper normal limit.
  • Poorly controlled acute or active infection; severe mental illness.
  • Suspected systemic or local lymphadenopathy on imaging.
  • Pregnant or lactating women; presence of other serious underlying diseases.
  • Currently participating in other clinical trials; refusal to provide informed consent.

Key Trial Info

Start Date :

November 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2027

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT07211815

Start Date

November 1 2025

End Date

June 1 2027

Last Update

October 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chifeng Tumor Hospital

Chifeng, Inner Mongolia, China, 024000